세계 글리코믹스 시장 규모는 2023년 15억 달러에 달했습니다. 향후 IMARC 그룹은 2032년까지 시장 규모가 41억 달러에 달하고, 2024년부터 2032년까지 11.17%의 연평균 성장률(CAGR)을 나타낼 것으로 예측했습니다. 대중들 사이에서 만성 질환이 만연하고, 당쇄 공학 기술에 대한 관심이 높아지고, 의약품 및 생물학적 제제 관련 위탁 연구 기관(CRO)의 수가 증가하는 것이 시장을 주도하는 주요 요인입니다.
글리코믹스는 생물학적 시스템에서 당질, 특히 당쇄에 대한 종합적인 연구에 초점을 맞춘 과학 분야입니다. 그 목적은 당 사슬의 구조, 구성, 기능 및 다른 생체 분자와의 상호 작용을 이해하는 것입니다. 연구자들은 글리콤을 분석하여 당 사슬이 생물학적 과정에 어떻게 영향을 미치고 건강과 질병에 어떻게 기여하는지 밝힐 수 있습니다. 이 다학제적 분야는 화학, 생화학, 분자생물학, 정보학의 측면을 결합하여 당사슬의 구조와 기능의 복잡성을 밝혀냅니다. 연구로 얻은 통찰력은 의학, 의약품 개발, 바이오마커 탐색, 개인 맞춤형 치료 등 다양한 분야에 영향을 미치고 있습니다.
세계 시장의 주요 원동력은 만성 질환의 유병률 증가입니다. 또한, 글리코 엔지니어링에 대한 관심이 높아지면서 시장을 뒷받침하고 있습니다. 글리코 엔지니어링은 치료제, 백신, 생명 공학 등 다양한 용도로 당 사슬을 변형하거나 조작하는 것을 포함하기 때문입니다. 이와는 별도로, 헬스케어 및 생명공학 발전에서 글리코믹스의 잠재력을 인식한 정부, 연구기관 및 민간 투자자들은 심층적인 연구 수행, 신기술 개발 및 글리코믹스 기반 제품의 상업화 탐구를 위한 투자를 제공함으로써 시장을 촉진하고 있습니다. 또한, 교육 및 훈련 분야에서도 전 세계적으로 인기가 높아지고 있습니다. 또한, 의약품 및 생물학적 제제의 연구 개발 및 생산에 종사하는 위탁연구기관(CRO)의 수가 증가하고 있는 것도 시장 성장을 가속하고 있습니다. 이 외에도 제약 산업의 확장, 임상시험 증가, 의료 인프라의 발전 등도 시장 성장에 영향을 미치고 있습니다.
연구개발 활동의 활성화
연구개발(R&D) 활동이 크게 증가하고 있습니다. 다양한 생물학적 과정에서 당쇄의 중요한 역할에 대한 이해도가 높아짐에 따라 이러한 분자의 연구와 조작에 대한 관심이 증가하고 있습니다. 연구자들과 제약회사들은 신약개발, 맞춤의료, 진단에 있어서 당쇄의 잠재적 응용 가능성을 탐구하는 연구에 투자하고 있습니다. 또한, 분석 기술과 기술의 지속적인 발전으로 연구 범위가 확대되고 있습니다. 또한, 학계, 산업계, 연구기관의 공동연구가 글리코믹스 연구 개발에 박차를 가하고 있습니다. 이러한 공동 연구는 다양한 전문 지식과 자원을 결합하여 혁신을 촉진하고 글리코믹스 기반 제품 개발을 가속화합니다. 또한, 다양한 이해관계자들의 협력은 지식의 확장, 신기술 개발, 연구 결과의 실용화에 기여하고 있습니다.
맞춤형 의료에 대한 수요 증가
개인맞춤의료란 유전적 체질이나 특정 특성에 따라 환자 개개인의 특성에 맞는 치료를 목적으로 하는 것으로, 최근 주목받고 있습니다. 글리코컴은 다양한 질병에 관여하고 진단 및 예후 예측을 위한 잠재적 바이오마커로 작용할 수 있기 때문에 맞춤의료에서 매우 중요한 역할을 하고 있습니다. 환자의 글리코컴을 분석하고 이해하는 능력은 표적 치료와 보다 정확한 의료 개입을 개발할 수 있게 합니다. 또한, 당쇄 마이크로어레이 및 당쇄 시퀀싱과 같은 당쇄 프로파일링 기술의 발전으로 질병에 특화된 당쇄 시그니처를 쉽게 식별할 수 있게 되었습니다. 이러한 발견은 당쇄 기반 진단, 맞춤 치료 및 동반 진단 개발에 유망하며, 글리코믹스 연구 및 제품에 대한 수요를 더욱 촉진하고 있습니다.
바이오마커 탐색에 대한 관심 증대
바이오마커 발굴 분야에서 글리코믹스는 큰 주목을 받고 있습니다. 당쇄는 암, 심혈관 질환, 감염성 질환 등 다양한 질환의 바이오마커로 유망한 가능성을 보여주고 있습니다. 바이오마커는 질병의 진단, 예후 및 치료 효과 모니터링에 중요한 역할을 하고 있습니다. 또한, 신뢰할 수 있고 특이적인 바이오마커를 식별하는 것이 질병 발견, 환자 계층화 및 치료법 선택에 있어 매우 중요하기 때문에 바이오마커 탐색에 대한 관심이 높아지면서 연구 수요가 증가하고 있습니다. 또한, 바이오마커 탐색 파이프라인에 글리코믹스의 통합은 진단학에 혁명을 일으키고 조기 개입을 가능하게 할 수 있는 잠재력을 가지고 있어 전체 시장 성장을 가속하고 있습니다. 또한, 이 연구는 다양한 질병과 관련된 특정 글리코믹스 패턴과 변화를 확인할 수 있는 특별한 기회를 제공합니다. 개인 또는 환자 코호트의 글리캄을 조사함으로써 연구자들은 진단 또는 예후 바이오마커로 작용할 수 있는 질병 특이적 당쇄 시그니처를 밝힐 수 있습니다.
The global glycomics market size reached US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.1 Billion by 2032, exhibiting a growth rate (CAGR) of 11.17% during 2024-2032. The growing prevalence of chronic diseases among the masses, the rising focus on glycoengineering techniques, and the growing number of contract research organizations (CROs) involved in drug and biologics are some of the major factors propelling the market.
Glycomics is a scientific field that focuses on the comprehensive study of carbohydrates, specifically glycans, in biological systems. It aims to understand the structure, composition, and functions of glycans, as well as their interactions with other biomolecules. By analyzing the glycome, researchers can determine how glycans influence biological processes and contribute to health and disease. This interdisciplinary field combines aspects of chemistry, biochemistry, molecular biology, and informatics to unravel the complexities of glycan structures and functions. The insights gained from the research have implications across various domains, including medicine, drug development, biomarker discovery, and personalized therapeutics.
The global market is primarily driven by the growing prevalence of chronic diseases. Moreover, the increasing focus on glycoengineering is supporting the market as glycoengineering involves the modification or manipulation of glycans for various applications, including therapeutics, vaccines, and biotechnology. Apart from this, Governments, research organizations, and private investors are recognizing the potential of glycomics in advancing healthcare and biotechnology and are providing investments to conduct in-depth studies, develop new technologies, and explore the commercialization of glycomics-based products, providing a boost to the market. Furthermore, it is gaining popularity in the field of education and training worldwide. Additionally, the growing number of contract research organizations (CROs) involved in drug and biologics development and production is augmenting the market growth. Other factors, such as expanding pharmaceutical industry, increasing number of clinical trials, and advancements in healthcare infrastructure, are also influencing the market.
Increasing Research and Development Activities
The market is experiencing a significant boost in research and development (R&D) activities. The growing understanding of the crucial roles played by glycans in various biological processes has increased interest in studying and manipulating these molecules. Researchers and pharmaceutical companies are investing in research to explore the potential applications of glycans in drug discovery, personalized medicine, and diagnostics. Moreover, the expanding scope of the research is driven by continuous advancements in analytical techniques and technologies. Furthermore, collaborations between academia, industry, and research institutions have fueled the growth of glycomics R&D. These collaborations bring together diverse expertise and resources, fostering innovation and accelerating the development of glycomics-based products. Additionally, the collaborative efforts between various stakeholders contribute to the expansion of knowledge, development of new technologies, and translation of research findings into practical applications.
Rising Demand for Personalized Medicine
Personalized medicine, which aims to tailor medical treatments to individual patients based on their genetic makeup and specific characteristics, is gaining prominence. It plays a pivotal role in personalized medicine as glycans have been implicated in various diseases and can serve as potential biomarkers for diagnostics and prognostics. The ability to analyze and understand the glycome of patients can enable the development of targeted therapies and more precise medical interventions. In addition, the advancements in glycomics profiling technologies, such as glycan microarrays and glycan sequencing, have facilitated the identification of disease-specific glycan signatures. These discoveries hold promise for the development of glycan-based diagnostics, personalized therapeutics, and companion diagnostics, further fueling the demand for glycomics research and products.
Increasing Focus on Biomarker Discovery
Glycomics has gained significant attention in the field of biomarker discovery. Glycans have shown promising potential as biomarkers for various diseases, including cancer, cardiovascular disorders, and infectious diseases. Biomarkers play a crucial role in disease diagnosis, prognosis, and monitoring treatment efficacy. Moreover, the growing focus on biomarker discovery has propelled the demand for research, as the identification of reliable and specific biomarkers is crucial for improving disease detection, patient stratification, and treatment selection. Furthermore, the integration of glycomics into biomarker discovery pipelines has the potential to revolutionize diagnostics and enable early intervention, driving the growth of the overall market. Also, the research offers a unique opportunity to identify specific glycan patterns or alterations associated with different diseases. By studying the glycome of individuals or patient cohorts, researchers can unveil disease-specific glycan signatures that can serve as diagnostic or prognostic biomarkers.
IMARC Group provides an analysis of the key trends in each segment of the global glycomics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, application and end user.
Enzymes
Glycosidases
Glycosyltransferases
Neuraminidases
Sialyltransferases
Others
Instruments
Mass Spectrometers
HPLC
MALDI-TOF
Array systems
Others
Kits
Glycan Labeling Kits
Glycan Purification Kits
Glycan Release Kits
Others
Reagents
Glycoproteins
Monosaccharides
Oligosaccharides
Others
Enzymes equipment dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes enzymes (glycosidases, glycosyltransferases, neuraminidases, sialyltransferases, and others), instruments (mass spectrometers, HPLC, MALDI-TOF, array systems, and others), kits (glycan labeling kits, glycan purification kits, glycan release kits, and others), reagents (glycoproteins, monosaccharides, oligosaccharides, and others). According to the report, enzymes represented the largest segment.
On the basis of the product, enzymes represent the largest product segment within the market. Enzymes play a crucial role in research and applications by facilitating the analysis and manipulation of glycans. Enzymes, such as glycosidases, glycosyltransferases, and glycosyl hydrolases, are utilized in various workflows, including glycan release, structural analysis, and glycan modification. Moreover, enzymes are essential for the enzymatic cleavage of glycans from glycoproteins or glycolipids, enabling the analysis of liberated glycans. The demand for enzymes in research and applications is driven by the growing need for robust and efficient enzymatic tools. Researchers and scientists rely on enzymes to accurately and selectively manipulate glycans, enabling comprehensive glycomics analysis and the development of glycan-based products. Additionally, advancements in enzyme engineering and optimization have led to the development of highly specific and efficient enzymes, further enhancing their utility in glycomics research.
Drug Discovery and Development
Diagnostics
Others
Drug discovery and development hold the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes drug discovery and development, diagnostics, and others. According to the report, drug discovery and development accounted for the largest market share.
On the basis of application, drug discovery and development represent the largest segment within the overall market. It plays a crucial role in advancing drug discovery and development processes by providing insights into the role of glycans in disease mechanisms, drug efficacy, and safety. Glycans are involved in various biological processes and have been linked to numerous diseases, including cancer, cardiovascular disorders, and infectious diseases. Understanding the glycan profiles and their interactions with proteins and cells is essential for identifying potential therapeutic targets and designing effective drugs. Moreover, the integration with drug discovery and development processes has led to the development of glycan-based therapies, companion diagnostics, and improved drug screening platforms. Also, the focus on targeting glycans in drug discovery and development has driven the demand for research and technologies, making it the largest application segment within the market.
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)
Academic and research institutes hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs). According to the report, academic and research institutes accounted for the largest market share.
Academic and research institutes represent the largest segment of the market. They play a vital role in driving research and advancements in the field. These institutions serve as the primary hubs for scientific research, knowledge generation, and innovation in the field. They are home to leading scientists, researchers, and experts who are actively involved in studying and exploring the complexities of glycans. These institutions also provide the necessary infrastructure, funding, and collaborative opportunities to support the research. They often house state-of-the-art laboratories equipped with advanced analytical instruments and technologies, enabling comprehensive glycan analysis and profiling. Furthermore, academic and research institutes contribute significantly to expanding the knowledge base through publications, scientific conferences, and collaborations. They foster interdisciplinary research collaborations, bringing together experts from various fields such as chemistry, biology, bioinformatics, and medicine.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest glycomics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.
Region-wise, North America exhibits a clear dominance in the market. North America is home to several renowned academic institutions, research organizations, and biotechnology companies that have made significant contributions to the research. These institutions have robust research infrastructure, state-of-the-art laboratories, and well-established collaborations, facilitating cutting-edge studies and innovation. Moreover, the region has a well-developed healthcare and biopharmaceutical sector, which drives the demand for research and applications. The presence of major pharmaceutical companies and biotech firms in North America leads to significant investments in the research for drug discovery, personalized medicine, and the development of glycan-based therapeutics. Furthermore, the region has a favorable regulatory environment and strong intellectual property protections that encourage innovation and commercialization of glycomics-based products. The region's well-defined regulatory frameworks provide clarity and guidance for research, ensuring the safety and efficacy of glycan-based diagnostics and therapeutics.
Companies in the market are involved in various activities related to glycomics research, product development, and commercialization. Several major companies are investing in research and development to advance the understanding of glycans, develop new technologies, and explore applications in various fields. They conduct studies to uncover the roles of glycans in disease mechanisms, identify glycan biomarkers, and understand glycan-protein interactions. Moreover, the companies in the market develop and manufacture products that support the research. This includes enzymes, kits, reagents, and instruments used in glycan analysis, glycan profiling, and glycan modification. These products help researchers in academia, pharmaceutical companies, and research institutes carry out glycomics experiments and investigations. Additionally, some companies focus on translating research into commercial applications. They develop and market glycan-based products for various industries, such as biopharmaceuticals, diagnostics, and nutraceuticals.
Agilent Technologies Inc.
Asparia Glycomics
Bruker Corporation
Danaher Corporation
Dextra Laboratories Limited (New Zealand Pharmaceuticals Limited)
Merck KGaA
New England Biolabs
RayBiotech Life Inc.
Shimadzu Corporation
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Waters Corporation.
In June 2023, Agilent Technologies Inc. launched Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.
In March 2023, Waters Corporation launched Next-Generation Alliance iS HPLC System aimed at reducing Up to 40% of Common Lab Errors. This new product helps laboratories manage operational risk, mitigate disruptions, and increase overall productivity.
In September 2022, Thermo Fisher Scientific Inc. launched the DynaSpin(TM) Single-Use Centrifuge system2. The system is specifically designed to provide an optimal single-use solution for large-scale cell culture harvesting. It also improves and streamlines harvesting for cell culture separation in single-use bioprocesses by reducing the number of depth filtration cartridges required to complete the harvest process.